Latterell Venture Partners
Venture capitalSan Ramon · Seed–Series A · 6 people tracked
Investment thesis
Latterell Venture Partners backs early-stage healthcare companies developing innovative technologies addressing large markets, led by passionate entrepreneurs. The firm combines venture capital, entrepreneurial, technical, clinical, and collaborative expertise to help founders build successful startups. LVP aims to assemble a portfolio of leading biotechnology and medical device companies that generate strong returns for its limited partners while delivering major new disease treatments benefiting patients worldwide.
Source: firm website, verified Aug 3, 2026.
Team · 6 people
from the firm's website & public directoriesWhat they invest in
from 8 of 30 portfolio companiesBiotech ×7Healthtech ×5Medical Devices ×3Hardware ×1
HQs:United States×7
Investments · 30 tracked
founders shown can be your intro path
Pulmonx develops the Zephyr Valve, a bronchoscopic device used to treat patients with severe COPD/emphysema without surgery.
BiotechHealthtechMedical DevicesSan Jose, US
GLENDON E. FRENCH(Executive Officer, Director)LAUREN CRISTINA(Executive Officer)inSri Radhakrishnan(Chief Technology Officer)inMICHAEL BAKER(Executive Officer, Director)in
BoardDANA G. MEAD, JR(Director)STEPHEN SALMON(Director)in
Co-investorsBand of AngelsHealthCapKaiser Permanente Ventures
BiotechEvanston, US
Joseph R. Moskal(Chief Scientific Officer)Torsten M. Madsen(Chief Marketing Officer)Ashish Khanna(Secretary & Chief Business Officer)Norbert G. Riedel(Chief Executive Officer)
BoardLiam Ratcliffe(Director)Terry P. Gould(Director)
Co-investorsBain Capital Life SciencesFrazier Life SciencesLongitude CapitalOUP (Osage University Partners)Agent CapitalHBM Healthcare Investments+2 more
Cancer pharmaceutical company targeting PI3 Kinase; acquired by Gilead for up to $600M.
Co-investorsFrazier Life Sciences
Developed pharmaceuticals for B-cell cancers and immune diseases; acquired by MedImmune for up to $175M.
Co-investorsAlta Partners
Developed a bio-erodable femoral closure device; acquired by Johnson & Johnson for up to $90M.
Specialty pharmaceutical company developing products for GI applications; IPO'd September 2013 (EVOK).
Evoke Pharma develops treatments for gastrointestinal disorders, focusing on advancing and commercializing GIMOTI, a nasal spray formulation for diabetic gastroparesis.
BiotechHealthtechMedical Devices
Cam L. Garner(Co-founder and Chairman)Matthew J. D'Onofrio(Co-founder & Chief Executive Officer)
Developed biotech research instruments for measuring molecular binding; acquired by Pall Corporation for $159M.
Developed lightweight portable oxygen concentrators; acquired by ResMed.
HealthtechAustin, US
John B. Rush(Executive Officer, Director)Daniel Jensen(Executive Officer)
BoardGeoff Pardo(Director)Stephen M. Salmon(Director)Richard Lin(Director)Roderick A. Young(Director)
Commercializing rapid DNA analysis technology for forensics; acquired by Thermo Fisher Scientific in 2018.
BiotechHardwareMedical Devices
Co-investorsQuestMark Partners
Specialty pharma treating Eosinophilic Esophagitis; acquired by Shire for up to $245M in 2015.
Co-investorsThe Vertical Group
Developed next-generation depression pharmaceuticals; acquired in 2015 for $560M upfront plus milestones.
BiotechEvanston, US
Joseph R. Moskal(Executive Officer)Amin Khan(Executive Officer)James Schulz(Executive Officer)Ronald M. Burch(Executive Officer)Norbert Riedel(Executive Officer, Director)Ashish Khanna(Executive Officer)
Co-investorsCota CapitalEcoR1 CapitalSofinnova Ventures
Developing cancer therapeutics targeting cancer precursor cells; IPO'd July 2013 (OMED).
Mereo BioPharma is a rare disease drug developer that funds and advances novel therapeutic candidates not progressed by their originating pharmaceutical or biotech companies, with lead programs in osteogenesis imperfecta and Alpha-1 Antitrypsin Deficiency-associated Lung Disease.
BiotechHealthtech
Co-investorsThe Vertical Group
Developed an atherectomy device for peripheral artery disease; acquired by Medrad (Bayer) for $125M.
Mountain View, US
Alan Jacobs(Executive Officer, Director)Jennifer Jacobs(Executive Officer, Director)
BoardJames Woody(Director)John Friedman(Director)Grace Colon(Director)Rodney Markin(Director)
Co-investorsThe Vertical Group
Co-investorsThe Vertical Group
Developed cancer therapeutics targeting the proteasome; acquired by Onyx Pharmaceuticals for up to $851M.
Co-investorsLightstone VenturesUS Venture Partners
Developed a percutaneous device to re-open chronically occluded vessels; acquired by Boston Scientific.
Developing cancer therapeutics based on apoptosis research; IPO'd December 2013.
Developed a glaucoma treatment device reducing intra-ocular pressure; acquired by Alcon/Novartis for up to $740M.
Developing oncology therapeutics for viral-induced tumors; went public February 2021 (VIRX).
Co-investorsaMoonBay City Capital
Viracta Therapeutics was a precision oncology company.
BiotechHealthtechCardiff, US
Co-investorsAisling Capital
Exits · 13
IPOs and acquisitions across the tracked portfolioPulmonx Corp.NASDAQ: LUNGCalistogaacq. by GileadCellective Therapeuticsacq. by MedImmuneEnsure Medicalacq. by Johnson & JohnsonForteBioacq. by PallInova Labsacq. by ResMedIntegenX Websiteacq. by Thermo Fisher ScientificMeritageacq. by ShireOncoMed Websiteacq. by Mereo BioPharmaPathwayacq. by MedradProteolixacq. by Onyx PharmaceuticalsRevascular Therapeuticsacq. by Boston ScientificTranscendacq. by Alcon
Portfolio news
latest coverage across their companiesPulmonx Corp. · defenseworld.net · Jul 19, 2026
Frequently asked questions
- How many investments has Latterell Venture Partners made?
- Latterell Venture Partners has 31 tracked investments, 13 of which have exited via acquisition or IPO.
- What stage does Latterell Venture Partners invest at?
- Latterell Venture Partners invests at the Seed, Series A stages.
- What is Latterell Venture Partners's typical check size?
- Latterell Venture Partners typically writes checks of $50K – $10M.
- What sectors does Latterell Venture Partners focus on?
- Latterell Venture Partners focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Latterell Venture Partners located?
- Latterell Venture Partners is headquartered in San Ramon, US.
- Does Latterell Venture Partners lead rounds?
- Yes, Latterell Venture Partners leads investment rounds.
- Who does Latterell Venture Partners co-invest with?
- Latterell Venture Partners most often shares deals with The Vertical Group, Frazier Life Sciences, Lightstone Ventures, among 18 tracked co-investors.
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Eight Roads Ventures is a venture capital firm that backs and partners with technology and healthcare companies.
GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.